SAR441255

SAR441255 is a synthetic peptide triagonist that acts as an agonist at the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). Structurally based on the exendin-4 sequence, it was developed to provide balanced activation of all three incretin receptors. Preclinical studies demonstrated superior metabolic outcomes—including weight loss and improved glycemic control—compared to dual GLP-1/GCG agonists. In healthy human subjects, single subcutaneous doses improved glycemic control and showed pharmacodynamic effects consistent with activation of all three target receptors. The development of SAR441255 was discontinued by the sponsor for reasons unrelated to safety[1][2][3][6].